JP7742832B2 - 嗜癖の治療および／または予防を必要とする対象の嗜癖の治療および／または予防におけるシチシンを含む組成物 - Google Patents

嗜癖の治療および／または予防を必要とする対象の嗜癖の治療および／または予防におけるシチシンを含む組成物

Info

Publication number
JP7742832B2
JP7742832B2 JP2022516412A JP2022516412A JP7742832B2 JP 7742832 B2 JP7742832 B2 JP 7742832B2 JP 2022516412 A JP2022516412 A JP 2022516412A JP 2022516412 A JP2022516412 A JP 2022516412A JP 7742832 B2 JP7742832 B2 JP 7742832B2
Authority
JP
Japan
Prior art keywords
cytisine
subject
weeks
smoking
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022516412A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548876A5 (https=
JP2022548876A (ja
JPWO2021050203A5 (https=
Inventor
エー． ジェイコブズ シンディ
エフ． カイン ダニエル
クラーク アンソニー
Original Assignee
アチーブ ライフ サイエンシーズ， インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アチーブ ライフ サイエンシーズ， インク． filed Critical アチーブ ライフ サイエンシーズ， インク．
Publication of JP2022548876A publication Critical patent/JP2022548876A/ja
Publication of JP2022548876A5 publication Critical patent/JP2022548876A5/ja
Publication of JPWO2021050203A5 publication Critical patent/JPWO2021050203A5/ja
Priority to JP2025011057A priority Critical patent/JP2025081331A/ja
Application granted granted Critical
Publication of JP7742832B2 publication Critical patent/JP7742832B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022516412A 2019-09-12 2020-08-14 嗜癖の治療および／または予防を必要とする対象の嗜癖の治療および／または予防におけるシチシンを含む組成物 Active JP7742832B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025011057A JP2025081331A (ja) 2019-09-12 2025-01-27 嗜癖の治療および／または予防を必要とする対象の嗜癖の治療および／または予防におけるシチシンを含む組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962899637P 2019-09-12 2019-09-12
US62/899,637 2019-09-12
US202062988890P 2020-03-12 2020-03-12
US62/988,890 2020-03-12
PCT/US2020/046308 WO2021050203A1 (en) 2019-09-12 2020-08-14 Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025011057A Division JP2025081331A (ja) 2019-09-12 2025-01-27 嗜癖の治療および／または予防を必要とする対象の嗜癖の治療および／または予防におけるシチシンを含む組成物

Publications (4)

Publication Number Publication Date
JP2022548876A JP2022548876A (ja) 2022-11-22
JP2022548876A5 JP2022548876A5 (https=) 2023-08-23
JPWO2021050203A5 JPWO2021050203A5 (https=) 2023-08-23
JP7742832B2 true JP7742832B2 (ja) 2025-09-22

Family

ID=74866435

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022516412A Active JP7742832B2 (ja) 2019-09-12 2020-08-14 嗜癖の治療および／または予防を必要とする対象の嗜癖の治療および／または予防におけるシチシンを含む組成物
JP2025011057A Pending JP2025081331A (ja) 2019-09-12 2025-01-27 嗜癖の治療および／または予防を必要とする対象の嗜癖の治療および／または予防におけるシチシンを含む組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025011057A Pending JP2025081331A (ja) 2019-09-12 2025-01-27 嗜癖の治療および／または予防を必要とする対象の嗜癖の治療および／または予防におけるシチシンを含む組成物

Country Status (11)

Country Link
US (3) US11083715B2 (https=)
EP (1) EP4027815B1 (https=)
JP (2) JP7742832B2 (https=)
KR (1) KR20220074895A (https=)
CN (4) CN119587493A (https=)
AU (1) AU2020346695A1 (https=)
BR (1) BR112022004519A2 (https=)
CA (1) CA3153405A1 (https=)
MX (1) MX2022002882A (https=)
WO (1) WO2021050203A1 (https=)
ZA (1) ZA202204075B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3153405A1 (en) * 2019-09-12 2021-03-18 Achieve Life Sciences, Inc. Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof
EP4399517A4 (en) * 2021-09-08 2025-10-15 Achieve Life Sciences Inc ANALYTICAL METHODS FOR EVALUATING THE PURITY OF CYTISINE
JP2024095092A (ja) * 2022-12-28 2024-07-10 株式会社日立製作所 生成装置、生成方法、および生成プログラム
WO2024226736A2 (en) * 2023-04-26 2024-10-31 Achieve Life Sciences, Inc. Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2125699B (en) 1982-02-22 1986-02-12 Bruss Ni Sanitarno Gigieniches Medicinal preparation having antinicotine effect and method for obtention thereof
WO1998018798A1 (en) * 1996-10-30 1998-05-07 Pfizer Inc. Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
CN104906669A (zh) * 2007-03-30 2015-09-16 菲利普莫里斯生产公司 用于输送药剂的装置和方法
CN103284319A (zh) * 2013-06-20 2013-09-11 昌宁德康生物科技有限公司 一种金雀花碱替代尼古丁口腔雾化液及其制备方法
WO2014205449A2 (en) * 2013-06-21 2014-12-24 Isis Pharmaceuticals, Inc. Compounds and methods for modulating apolipoprotein c-iii expression for improving a diabetic profile
JP6324964B2 (ja) 2013-08-23 2018-05-16 久光製薬株式会社 貼付剤
PL409829A1 (pl) * 2014-10-18 2016-04-25 Łukasz Zalewski Płyn z cytyzyną do elektronicznych papierosów
GB201602145D0 (en) * 2016-02-05 2016-03-23 Achieve Pharma Uk Ltd Salt
EP3658561A1 (en) * 2017-07-24 2020-06-03 Achieve Pharma UK Limited Cytisine salts
CA3153405A1 (en) * 2019-09-12 2021-03-18 Achieve Life Sciences, Inc. Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Achieve Life Sciences，Achieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2b ORCA-1 Dose-Selection Trial，Press Release，2019年06月11日
BARBOZA, J.L. et al.，Expert Opin Pharmacother，2016年，Vol. 17, No. 11，pp. 1483-1493

Also Published As

Publication number Publication date
EP4027815A4 (en) 2023-06-07
AU2020346695A1 (en) 2022-04-28
WO2021050203A1 (en) 2021-03-18
KR20220074895A (ko) 2022-06-03
JP2022548876A (ja) 2022-11-22
EP4027815A1 (en) 2022-07-20
CN114727647A (zh) 2022-07-08
US20210330652A1 (en) 2021-10-28
CN118286217A (zh) 2024-07-05
US20210077475A1 (en) 2021-03-18
EP4027815B1 (en) 2026-04-15
CN119564619A (zh) 2025-03-07
US20210077473A1 (en) 2021-03-18
CN119587493A (zh) 2025-03-11
MX2022002882A (es) 2022-05-10
US11083715B2 (en) 2021-08-10
CA3153405A1 (en) 2021-03-18
ZA202204075B (en) 2023-11-29
JP2025081331A (ja) 2025-05-27
US11083716B2 (en) 2021-08-10
BR112022004519A2 (pt) 2022-05-31

Similar Documents

Publication Publication Date Title
JP7742832B2 (ja) 嗜癖の治療および／または予防を必要とする対象の嗜癖の治療および／または予防におけるシチシンを含む組成物
Henningfield et al. Pharmacotherapy for Nicotine Dependence 1
Newmeyer et al. Subjective and physiological effects, and expired carbon monoxide concentrations in frequent and occasional cannabis smokers following smoked, vaporized, and oral cannabis administration
Blondal et al. The effects of fluoxetine combined with nicotine inhalers in smoking cessation‐a randomized trial
Upadhyaya et al. Bupropion SR in adolescents with comorbid ADHD and nicotine dependence: a pilot study
US20120225949A1 (en) Compositions and methods for treating bipolar disorder
Wagen et al. Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive pulmonary disease
CN120641090A (zh) 向哺乳期女性施用索安非托的方法
TW202102219A (zh) 使用氘化右旋美沙芬(dextromethorphan)及奎尼丁(quinidine)治療精神分裂症之負面徵候之方法
Harlivasari et al. The role of twice-daily N-acetylcysteine (NAC) 2400 mg in smoking cessation: a randomized, placebo-controlled trial in Indonesia
Bittoun A combination nicotine replacement therapy (NRT) algorithm for hard-to-treat smokers
KR20260016478A (ko) 필요한 대상체의 중독 치료 및/또는 예방에 시티신을 포함하는 조성물
Suchanek Hudmon et al. Current approaches to pharmacotherapy for smoking cessation
US20260027068A1 (en) Methods of administering r-ketamine
US20250073186A1 (en) Combination treatment methods
Guidance Mental Health Clinician Guidance for Managing People’s Smoking Cessation
Wise et al. A review of nonpharmacologic and pharmacologic therapies for smoking cessation.
Al-Hait et al. A narrative review of smoking cessation practices in Jordan
EP3579923A1 (en) Treatment of asthma with cysteamine
Sinclair et al. Evidence-based consensus guidelines for the pharmacological management of substance dependence: Recommendations from the British Association for Psychopharmacology
Clements Medications for Smoking Cessation
Sullivan et al. State of the art reviews: smoking cessation: a review of treatment considerations
HK40060751A (en) Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine
Shiffman et al. Nicotine Delivery Systems

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230810

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230810

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250623

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250819

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250909

R150 Certificate of patent or registration of utility model

Ref document number: 7742832

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150